Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Wyeth
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
Revaccination with Pneumococcal Conjugate Vaccine - Characterization of the Immune Response after Polysaccharide (REPLAY)
To characterize the immune response by ELISA and OPA at approximately one month after vaccination to a single dose of PCV13 challenge in children vaccinated with a primary series (3 or 2 doses) of PCV...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Postauthorization Safety Surveillance Study of Patients Switching to ReFacto AF From ReFacto or Other Factor VIII Products in Usual Care Settings
To evaluate clinically significant FVIII inhibitor development in a large number of severe hemophila A patients treated with ReFacto AF in usual use settings.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company
MAJ Il y a 5 ans
Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate
To evaluate clinical efficacy and safety of 4 SBI-087 SC dosing regimens versus placebo in seropositive subjects with active RA on a stable background of MTX
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF SRA-333 IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH DONEPEZIL AS ACTIVE CONTROL
The primary objective is to determine the safety, tolerability, and efficacy of 3 doses of SRA-333 in patients with mild to moderate AD over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair
The primary objective of this study is to assess the efficacy of IV MOA-728 in subjects who have undergone repair of large (³10 cm) ventral hernias, with or without a mesh prosthesis via laparotomy or...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Consumer Healthcare
MAJ Il y a 5 ans
A Safety Study of TDS-943
Safety - to assess Gastric Mucosal Prostaglandin Synthesis between comparitors
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Wyeth
MAJ Il y a 5 ans
Wyeth 3066K1-404 : Essai de phase 2-3 randomisé évaluant l'efficacité et la tolérance du temsirolimus et du sorafénib, en traitement de second ligne, chez des patients ayant un cancer du rein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy.
Pays
France
Organes
Rein
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment
To describe the effect on subjects in whom PSO has responded to initial treatment with ETN of 2 different strategies for managing a good response or complete response (PGA = 1or 0) over a 52-week time...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women with locally advanced or metastatic breast cancer
Assessment of overall progression free survival (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
MAJ Il y a 5 ans
A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma
To assess the efficacy and safety of etanercept 25 mg twice weekly in subjects with moderate to severe persistent asthma
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
1
2
3
4
5
6
7
8
9
10
Suivant